Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,986 shares of the biopharmaceutical company’s stock after selling 1,633 shares during the period. iA Global Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $13,649,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $932,571,000. Global Assets Advisory LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $339,594,000. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares in the last quarter. First Trust Advisors LP boosted its position in Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after acquiring an additional 195,902 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.5 %

NASDAQ REGN traded up $5.76 on Friday, reaching $1,184.69. The stock had a trading volume of 405,354 shares, compared to its average volume of 467,334. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $1,100.29 and a two-hundred day moving average price of $1,010.55. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The firm has a market capitalization of $130.54 billion, a price-to-earnings ratio of 35.00, a P/E/G ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.79 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the sale, the chief executive officer now directly owns 64,198 shares in the company, valued at approximately $65,162,253.96. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 787 shares of the company’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the sale, the chief executive officer now owns 64,198 shares in the company, valued at approximately $65,162,253.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 9,064 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the completion of the transaction, the chief executive officer now owns 55,134 shares of the company’s stock, valued at approximately $55,984,717.62. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,239 shares of company stock worth $23,933,880. Corporate insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,108.45.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.